Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-10-10

Clinical Trial Update: Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of oral DS107 in moderate to severe atopic dermatitis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DS107

Snippet

Sponsor: DS Biopharma | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2022-10-10